Feasibility of abiraterone acetate treatment in patients with metastatic castration-resistant prostate cancer and atrial fibrillation

摘要

Background Abiraterone acetate (AA), a selective inhibitor of the CYP17 enzyme, demonstrated a significant improvement in the treatment of patients with metastatic castration-resistant prostate cancer. The risk of endocrine side effects, mainly an increased adrenal mineralocorticoid production, could limit its use in patients with atrial fibrillation. Methods We retrospectively reviewed the clinical records of 85 metastatic castration-resistant prostate cancer patients treated with AA at our institutions and identified six patients suffering from concomitant atrial fibrillation. Results In these six patients, the median duration of AA treatment was 11.5?months (range 4–22?months) with a biochemical response in three patients. No significant cardiac events were observed during the treatment. Conclusion Our data suggest that AA may be safely administered in patients with atrial fibrillation.